Markian M Stec

发表

Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate.

N. Chen, J. Treanor, C. Dominguez, 2007, Journal of medicinal chemistry.

Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides.

N. Chen, J. Treanor, V. Viswanadhan, 2007, Journal of medicinal chemistry.

Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides.

N. Chen, C. Fotsch, A. Bannon, 2005, Bioorganic & medicinal chemistry letters.

Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles.

R. Kunz, Jiandong Zhang, S. Chmait, 2014, Journal of medicinal chemistry.

Substituted aryl pyrimidines as potent and soluble TRPV1 antagonists.

J. Treanor, P. Chakrabarti, Yunxin Y Bo, 2008, Bioorganic & medicinal chemistry letters.

Stereoselective synthesis of an advanced taxusin intermediate: an application of the type 2 intramolecular Diels–Alder reaction

S. L. Gwaltney, K. Shea, Markian M Stec, 2003 .

Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511.

Daniel J. Freeman, J. McCarter, Nancy Zhang, 2012, Journal of medicinal chemistry.

Structure-activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: investigations of various 6,5-heterocycles to improve metabolic stability.

Daniel J. Freeman, J. McCarter, Nancy Zhang, 2011, Journal of medicinal chemistry.

The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors.

J. McCarter, D. Whittington, Nancy Zhang, 2015, Bioorganic & medicinal chemistry letters.

Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists.

P. Chakrabarti, E. Doherty, A. Bannon, 2008, Journal of medicinal chemistry.

Synthesis of novel melanocortin 4 receptor agonists and antagonists containing a succinamide core.

C. Fotsch, Markian M Stec, N. Xi, 2004, Bioorganic & medicinal chemistry letters.

P450-mediated O-demethylated metabolite is responsible for rat hepatobiliary toxicity of pyridyltriazine-containing PI3K inhibitors.

D. Branstetter, H. Lebrec, R. Subramanian, 2014, Toxicological sciences : an official journal of the Society of Toxicology.